Member Info for easyp

I also made a modest top up this afternoon in the expectation of either a bid or scientific news on the extended trial.

Yes its a risk to buy more but the potential upside is considerable.

A bit disappointed by the sp today as US oil reserves at multi year low and prices up. I checked the share trade data and again could not really see the justification for a 2.3% drop....meh! Market Makers!

After a reiteration to buy with a target of 820p by citigroup just over a week ago we are down 2% this morning.

Clearly all shares involved in gambling are out of favour with the markets this Autumn.

Some good posts below on strategy, much appreciated to hear other views. I think the case is to be willing to buy at these low prices and hold for better news over the next 12 months. Sure, some will day trade and speculate but while not without risks the patient investor might do very well here.

From Sean Wade this morning:

"This is referring to an article last week in El Pais and is speculation on the part of the journalist.

I assure you that we will keep the market informed of any price sensitive information."

Just a snippet from AZN news but worth noting that places like China are willing to try and buy innovative drugs and it is a massive market. Not sure if Lupus is a more western problem though but it is a disease AZN has worked on and failed so even they might be interested in IMM.

"AstraZeneca has been on a tear in China, more than doubling its sales since 2012, helped by regulatory reforms to fast-track new drugs, and today generates 18 percent of revenue in the country -- a far higher proportion than rivals.

Yet Soriot is anxious to do more to keep doctors and government officials on-side in the world's second-biggest drugs market, as soaring demand strains the state insurance system and squeezes medicine prices.

The company's underlying conviction is that it has the right medicines across chronic diseases like cancer, diabetes and respiratory disorders to win in China.

Soriot believes that can keep AstraZeneca growing in a pivotal market in the coming years, even though annual growth is likely to slow to nearer 15 percent from the breakneck 33 percent seen in the first half of 2018.

The company has moved quickly to exploit China's new-found willingness to use innovative Western drugs"

I have purchased and sold a couple of times over the past 5 years and made a little money while others have held for the dividend and relative safety of AZ.

I am tempted to buy back in after a good run with OXB but fear that Trump will come after big Pharma in the USA over drug prices. So while the AZ drug pipeline look good I am going to sit on my hands for a while longer. To those that have bought and held over three years the possibility of a dip in sp related to drug pricing is not a big issue for someone looking to time an entry it is.

Thanks for the link technically beyond my understanding but I gather the geology in this area makes conventional seismology unreliable so new methods will hopefully be a better predictor of where the oil is.

Alternatively they could just get drilling and see!

Played a similar game and therefore made some money on PMG previously but believe a bid or re rating possibly on its way. I would plan to take some profits at 80p ish depending on news and keep a few thousand for the longer term.

FT reports a director Tom Hyland purchased just over 115,000 shares this week.

Encouraging news imo.

I will be topping up on Monday see FT today re Director buying:

British bookies are hoping that Americans will be keen on sports betting after legislation banning this type of gambling was overturned earlier this year. In August, William Hill announced it would provide technology and risk management services to 11 casinos in Mississippi and another in West Virginia. Last week, the group announced it would partner with Eldorado Resorts for digital and land-based sports betting and online gaming in the US, initially comprising 21 properties across 11 states and a customer base of 23m people.

Management is perhaps thinking the so-called “land of opportunity” will compensate for tougher trading in its UK retail business. At the half-year results last month, a £916m impairment, charged mainly on its UK retail assets following the decision to cut the maximum stake allowed on fixed-odds betting terminals (FOBTs), wiped out group profits. Still, management seems confident in the future: chief financial officer Ruth Prior — along with other connected parties — has spent more than £100,000 topping up her stake.

Back to where we were 3 months ago, interesting if erratic ride but can we have some sustained upward movement?

Is this a likely support level and if so why? 10p has been banded about in previous posts. I remain disappointed/in denial about why a company with cash and a potential drug for Lupus is sinking this far this quickly.

And cue Nolopus.....

The transformation imo is that the science and the results are driving orders and income. The sp has dropped from year highs despite the very positive recent news so content to add a few more and wait.

Not yet, wait for all of the required permits to be granted and construction finished. Realistically, I think the permits by end of year, any later and I will be reducing my stake and investing it in UUUU.

Off topic a little but I thought this might amuse board members. The Daily Telegraph reported on results for Energean a recently listed oil and gas explorer. They have £1 billion in debt and produce 3801 bopd which along with I assume some gas and stated oil reserves of 349m barrels saw them make a profit and their sp is £5.3.

According to Analysts at Cantor Fitzgerald noted: “All of the comparative numbers are largely irrelevant as Energean is a hugely different beast from a year ago.”

I like to think that people will be saying the same of AMER in a year or two from now!

https://www.telegraph.co.uk/business/2018/09/12/energean-swings-profit-ftse-debut/

Down 1% as markets open not quite what I had expected so off to buy a few more!

212p is getting silly imo. Oil at $80 barrel tax case ongoing wtf?

https://lupusnewstoday.com/2018/06/04/lupuzor-benefits-european-lupus-patients-phase-3-trial-data/?amp

There is something very odd about a phase three trial where US and UK patients see such different results. The extension trial and a review of the original trial might reveal why there was such a marked difference. Hopefully the money will last long enough to deliver a result.

Thanks Baht good luck with your investments.